SYN - Synthetic Biologics, Inc.
| Previous Close | 2.55 |
| Open | 2.55 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 900 |
| Day's Range | 2.55 - 2.85 |
| 52 Week Range | 2.45 - 36.75 |
| Volume | 127,716 |
| Avg. Volume | 32,822 |
| Market Cap | 10.448M |
| Beta | 1.60 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.18 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.00 |
- Benzinga•2 days ago
What Goes Through The Mind of A Trader When Taking A Position?
I’ve spoken at length about the technical and charting factors that I take account of when looking for trading setups. Obviously momentum is the main factor that I prioritize, along with the stock’s recent ...
- GlobeNewswire•6 days ago
Consolidated Research: 2018 Summary Expectations for Fulton Financial, Leidos, Principal Financial Group, Quanta Services, Synthetic Biologics, and Sterling — Fundamental Analysis, Key Performance Indications
NEW YORK, Aug. 13, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Fulton ...
- Associated Press•11 days ago
Synthetic Biologics: 2Q Earnings Snapshot
On a per-share basis, the Rockville, Maryland-based company said it had a loss of 3 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
- PR Newswire•11 days ago
Synthetic Biologics Reports Second Quarter 2018 Operational Highlights and Financial Results
-- SYN-004 End of Phase 2 Meeting with U.S. Food & Drug Administration on Track for Third Quarter of 2018 -- -- Conference Call Today, August 8, 2018, at 4:30 p.m. (EDT) -- ROCKVILLE, Md. , Aug. 8, 2018 ...
- ACCESSWIRE•11 days ago
Synthetic Biologics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Synthetic Biologics, Inc. (NYSE American: SYN ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 4:30:00 ...
- Simply Wall St.•11 days ago
Is Now The Time To Bet On The Healthcare Sector And Synthetic Biologics Inc (NYSEMKT:SYN)?
Synthetic Biologics Inc (NYSEMKT:SYN), a US$15.98m small-cap, is a healthcare company operating in an industry, which faces key trends such as rising demand fuelled by an aging population and theRead More...
- PR Newswire•18 days ago
Synthetic Biologics Announces Reverse Stock Split
ROCKVILLE, Md., Aug. 1, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today a reverse stock split of its issued and outstanding common stock, par value $0.001 per share, at a ratio of one (1) share of common stock for every thirty-five (35) shares of common stock, effective August 10, 2018 (the "Effective Date"). The Company's common stock will begin trading on a split-adjusted basis when the market opens on August 13, 2018. The reverse stock split was authorized by the Company's Board of Directors on July 31, 2018.
- PR Newswire•19 days ago
Synthetic Biologics to Report Second Quarter 2018 Operational Highlights and Financial Results on August 8, 2018
-- Conference Call Scheduled for Wednesday, August 8, 2018 at 4:30 p.m. EDT -- ROCKVILLE, Md. , July 31, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company ...
- ACCESSWIRE•2 months ago
Stock Performance Review on Sesen Bio and Three Other Biotech
LONDON, UK / ACCESSWIRE / June 20, 2018 / If you want a free Stock Review on SESN sign up now at www.wallstequities.com/registration. All you have to do is sign up today for this free limited time offer by clicking the link below.
- PR Newswire•3 months ago
Synthetic Biologics Announces Acceptance of Compliance Plan by NYSE American
ROCKVILLE, Md., May 22, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, announced today that the NYSE American LLC (the "Exchange") has accepted the Company's plan of compliance (the "Plan") for continued listing on the Exchange. As previously reported, on March 2, 2018, Synthetic Biologics received a letter from NYSE American Staff indicating that the Company is not in compliance with certain continued listing standards relating to stockholders equity as set forth in Part 10, Section 1003 of the NYSE American Company Guide (the "Guide"). Based on the Company's 2017 annual report on Form 10-K, the Company is below compliance with Part 10, Section 1003(a)(iii) of the Guide since it reported stockholders' equity of less than $6 million and net losses in five of its most recent fiscal years as of December 31, 2017.
- ACCESSWIRE•3 months ago
Stock Performance Review on Tesaro and Three Other Biotech Industry
LONDON, UK / ACCESSWIRE / May 21, 2018 / If you want a free Stock Review on TSRO sign up now at www.wallstequities.com/registration. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Surface Oncology Inc. (SURF), Synthetic Biologics Inc. (NYSE AMER: SYN), Teligent Inc. (NASDAQ: TLGT), Tesaro Inc. (NASDAQ: TSRO).
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of SYN earnings conference call or presentation 8-May-18 8:30pm GMT
Q1 2018 Synthetic Biologics Inc Earnings Call
- Benzinga•3 months ago
Benzinga's Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 8) CONMED Corporation (NASDAQ: CNMD ) Enanta Pharmaceuticals Inc ...
- Associated Press•3 months ago
Synthetic Biologics: 1Q Earnings Snapshot
The Rockville, Maryland-based company said it had a loss of 2 cents per share. The company's shares closed at 25 cents. A year ago, they were trading at 46 cents. _____ This story was generated by Automated ...
- PR Newswire•3 months ago
Synthetic Biologics Reports First Quarter 2018 Operational Highlights and Financial Results
-- Preliminary Agreement Reached with FDA on Proposed Phase 3 Clinical Trial Synopsis for SYN-004 (ribaxamase) -- -- Conference Call Today, May 8, 2018, at 4:30 p.m. (EDT) -- ROCKVILLE, Md. , May 8, 2018 ...
- PR Newswire•4 months ago
Synthetic Biologics to Report First Quarter 2018 Operational Highlights and Financial Results on May 8, 2018
-- Conference Call Scheduled for Tuesday, May 8, 2018 at 4:30 p.m. EDT -- ROCKVILLE, Md. , April 26, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company ...
- PR Newswire•4 months ago
Synthetic Biologics Provides Update on Development of SYN-004 (ribaxamase), for the Prevention of C. difficile Infection
ROCKVILLE, Md., April 23, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today announced that it has preliminary agreement from the U.S. Food & Drug Administration (FDA), on a proposed clinical trial synopsis for its planned Phase 3 clinical trial for SYN-004 (ribaxamase). In accordance with recommendations and guidance received from the FDA, the Company expects the Phase 3 trial to include separate co-primary endpoints designed to evaluate the efficacy and safety of ribaxamase in a patient population being treated with a representative selection of intravenous (IV) beta-lactam antibiotics.
- PR Newswire•5 months ago
Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan
ROCKVILLE, Md., March 7, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today announced it has received written communication from NYSE American LLC (the "Exchange"), the Company's current listing exchange, stating that it is not in compliance with certain continued listing standards as set forth in the NYSE American Company Guide. In order to maintain its listing, the Company intends to submit a plan of compliance by April 3, 2018 addressing how it intends to regain compliance with certain Exchange continued listing standards by September 2, 2019. If the plan is accepted, the Company may be able to continue its listing but will be subject to periodic reviews by the Exchange.
- Thomson Reuters StreetEvents•6 months ago
Edited Transcript of SYN earnings conference call or presentation 22-Feb-18 1:30pm GMT
Full Year 2017 Synthetic Biologics Inc Earnings Call
- PR Newswire•6 months ago
Synthetic Biologics Reports 2017 Year End Operational Highlights and Financial Results
-- Company Provides Update on Late-stage Microbiome-focused Product Candidates -- -- Conference Call Today, February 22, 2018, at 8:30 a.m. (EST) -- ROCKVILLE, Md. , Feb. 22, 2018 /PRNewswire/ -- Synthetic ...
- ACCESSWIRE•6 months ago
Synthetic Biologics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 22, 2018 / Synthetic Biologics, Inc. (NYSE: SYN ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 22, 2018 at 8:30 AM Eastern ...
- PR Newswire•6 months ago
Synthetic Biologics to Report 2017 Year End Operational Highlights and Financial Results on February 22, 2018
-- Conference Call Scheduled for Thursday, February 22, 2018 at 8:30 a.m. EST -- ROCKVILLE, Md. , Feb. 15, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company ...
- PR Newswire•8 months ago
Synthetic Biologics to Present at the Biotech Showcase™ 2018 Conference
ROCKVILLE, Md. , Jan. 2, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore ...
